Back to News
Market Impact: 0.1
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
Source: gurufocus.com
Healthcare & Biotech
The headline says data for Skyrizi (risankizumab) and Rinvoq (upadacitinib) at UEGW highlight long-term clinical and endoscopic outcomes across inflammatory bowel disease. The provided text includes no study results, numerical data, or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- AI rapidly improving, could vastly boost U.S. GDP, Anthropic's Clark tells policymakers
- Susan Dell is the one running the Dells’ $10 billion giving operation—and her biggest bets are on kids, health care, and UT Austin
- Kenya confirms four more Ebola cases, bringing total to seven
- As Israel blocks PA funding, the West Bank’s healthcare system is failing
- Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share
- AbbVie's Dividend Keeps Climbing. Is It Still a Buy for Income Investors?